topotecan
topotecan is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including HYCAMTIN. Available dosage form: capsule.
Drug details
- Generic Name
- topotecan
- Brand Names
- HYCAMTIN
- Application Number
- NDA020981
- Sponsor
- Sandoz Inc
- NDC Codes
- 2
- Dosage Forms
- CAPSULE
- Routes
- ORAL
- Active Ingredients
- TOPOTECAN HYDROCHLORIDE
Indications and Usage
1 INDICATIONS AND USAGE Topotecan Injection is indicated for the treatment of: small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the Phase 3 study) or at least 90 days (in the Phase 2 studies) after chemotherapy [see Clinical Studies ( 14 ) ] . Topotecan Injection in combination with cisplatin is indicated for the treatment of: stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. Topotecan is a topoisomerase inhibitor indicated for: small cell lung cancer sensitive disease after failure of first-line chemotherapy. ( 1 ) combination therapy with cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. ( 1 )